Mereo BioPharma Files Q1 2025 10-Q Report

Ticker: MREO · Form: 10-Q · Filed: May 13, 2025 · CIK: 1719714

Mereo Biopharma Group PLC 10-Q Filing Summary
FieldDetail
CompanyMereo Biopharma Group PLC (MREO)
Form Type10-Q
Filed DateMay 13, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, biopharma

TL;DR

Mereo BioPharma's Q1 2025 10-Q is in. Check financials.

AI Summary

Mereo BioPharma Group plc filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations. Key financial data and operational details are presented in this quarterly report.

Why It Matters

This filing provides investors with an update on Mereo BioPharma's financial health and operational progress for the first quarter of 2025, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Mereo BioPharma is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 20250331 — Period End Date (The report covers the financial period ending on this date.)
  • 20250513 — Filing Date (The date the report was officially submitted to the SEC.)

Key Players & Entities

  • Mereo BioPharma Group plc (company) — Filer of the 10-Q report
  • 20250331 (date) — Conformed period of report
  • 20250513 (date) — Filed as of date
  • 001-38452 (company) — SEC file number
  • Setrusumab BPS-804UX143 (company) — Product candidate mentioned

FAQ

What is the reporting period for this 10-Q filing?

The conformed period of report is 20250331, meaning it covers the quarter ending March 31, 2025.

When was this 10-Q filing submitted to the SEC?

The filing was submitted on 20250513.

What is the SEC file number for Mereo BioPharma Group plc?

The SEC file number is 001-38452.

What is the Central Index Key (CIK) for Mereo BioPharma Group plc?

The Central Index Key for Mereo BioPharma Group plc is 0001719714.

Does the filing mention any specific product candidates?

Yes, the filing mentions 'Setrusumab BPS-804UX143' in the context of operating segments.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Mereo BioPharma Group plc (MREO).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.